Corpectomy Procedure / Courtesy of YouTube grspineclinic

NuVasive, Inc.’s Monolith corpectomy system, which was originally cleared for commercial sale by the FDA in 2015 for thoracolumbar procedures, can now be used for cervical procedures.

On November 30, 2018, the FDA granted NuVasive 510(k) clearance for expanded use of the Monolith corpectomy system after almost nine months of review.

A corpectomy procedure removes the vertebral body and adjoining discs.

The expanded clearance addresses tumor, trauma and degenerative disorders of the cervical spine.

According to FDA documents, the Monolith is a vertebral body replacement system manufactured from polyetheretherketone (PEEK) Optima LT-1 and is made up of two primary components: a core and a set of endcaps.

“The core is offered in a variety of shapes and sizes to fit individual pathology and anatomical conditions of the patient. The modular standard and railed endcaps are offered in multiple footprints and lordosis options.”

“The device contains pins made of either titanium alloy or tantalum…to serve as radiopaque markers. The system is provided non-sterile and is designed to be sterilized by the user before each use.”

Indications for Use

The FDA document states the system is indicated for “use in the cervical spine (C3-C7 vertebral bodies) in skeletally mature patients to replace a diseased or damaged vertebral body caused by tumor, fracture, or osteomyelitis, or for reconstruction following corpectomy performed to achieve decompression of the spinal cord and neural tissues in cervical degenerative disorders.”

Following removal of the vertebral body and disc, the device is used with supplemental fixation cleared by the FDA for use in the cervical spine. “These implants are intended for use with autograft or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft, as an adjunct to fusion.”

Additionally, the system is also intended to restore the “integrity of the spinal column even in the absence of fusion for a limited time period in patients with advanced stage tumors involving the cervical spine in whom life expectancy is of insufficient duration to permit achievement of fusion, with bone graft used at the surgeon’s discretion.”

Leave a comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.